Clinical Study--WecLac® B. animalis subsp. lactis BLa80 Adjuvant Quadruple Therapy

0
330

Clinical summary

[1] The current clinical treatment of Helicobacter pylori mainly uses a combination of antibiotics, which is prone to recurrence. In addition, irrational use of antibiotics can cause some adverse reactions.

 

[2] This clinical efficacy study was carried out by the Wecare Probiotics Research Institute in cooperation with relevant medical institutions. The purpose is to evaluate the conventional quadruple therapy combined with the probiotic Bifidobacterium animalis subsp lactis BLa80 in the treatment of Helicobacter pylori (Hp) infection, and the Clinical efficacy of adverse drug reactions during antibiotic treatment.

 

[3] This study proves that Bifidobacterium animalis subsp lactis BLa80 has a good adjuvant therapeutic effect in the eradication of Helicobacter pylori (Hp) quadruple therapy, significantly improving the severity of patients' gastrointestinal symptoms and significantly reducing the risk of drug treatment—incidence of nausea as an adverse reaction.

 

Strain clinical research

Research purpose: Effect of BLa80 adjuvant quadruple therapy on gastrointestinal adverse reactions in the eradication treatment of Helicobacter pylori (H. pylori)

 

Research methods

● Subjects: 100 cases in total

● Inclusion criteria: Age 18-70 years old, 13C or 14C-UBT positive

● Oral probiotic treatment for 2 weeks

 

Visits 1-4:

● Fill out the questionnaire: GSRS rating scale

● Collect stool samples for sequencing

 

Placebo: bismuth quadruple + 3.0g maltodextrin/Day

Probiotics: Bismuth quadruple + 3.0g BLa80 10 billion CFU/Day

 

● Bifidobacterium animalis subsp lactis BLa80 significantly improved the patient’s GSRS score and improved the patient’s gastric discomfort symptoms

 

The total GSRS score (severity of gastrointestinal symptoms) of the patients after H. <0.001).

 

● Bifidobacterium animalis subsp lactis BLa80 significantly reduces the incidence of gastrointestinal adverse reactions (nausea) during drug treatment

 

 

 

Analysis conclusion

In the eradication treatment of Helicobacter pylori, the probiotic bifidobacterium animalis subsp lactis BLa80 adjunct to conventional quadruple therapy showed a high eradication rate. At the same time, after probiotic BLa80 was used as an adjuvant treatment for Hp, the patient's gastrointestinal symptom rating score (GSRS) was significantly lower than that of the placebo group, significantly improving the patient's clinical symptoms (p < 0.05), and patients in the probiotic BLa80 group experienced symptoms during treatment. The incidence of nausea was significantly lower than in the placebo group (p < 0.05), indicating that adding probiotic BLa80 may help reduce adverse effects caused by conventional antibiotic treatment.

Site içinde arama yapın
Sponsorluk
Title of the document
Sponsorluk
ABU STUDENT PACKAGE
Kategoriler
Read More
Other
Glance Sports: Your Courtside Pass to NBA October Madness
"Sports are the common denominator in the world that brings everyone together." - Kareem...
By Glance Technologies 2024-11-25 05:54:08 0 633
Other
Education and Learning Analytics Market Size, Share Trends Report
IMARC Group has recently released a new research study titled “Education and Learning...
By Alex Smith 2025-02-19 07:27:30 0 324
Other
Top 5 Conversational Marketing Trends to Watch in 2025
It’s not just about AI and automation, it’s about creating deeper, human-like...
By SalesMark Global 2025-02-17 05:42:24 0 325
Film
Balthazar Viral Video On Social Media X Trending Now. jra
🌐 CLICK HERE 🟢==►► WATCH NOW 🔴 CLICK HERE 🌐==►► Download Now...
By Guifet Guifet 2025-02-18 17:11:25 0 293
Other
Single-Use Bioprocessing Market Size, Share & Growth Report 2024-2033
Single-Use Bioprocessing Market Report The market research report on the Single-Use...
By Sahil Rane 2025-01-08 18:21:36 0 531
Ayema https://ayema.ng